- When I first began writing articles, and doing radio
show interviews about the New York West Nile outbreak I mentioned the OraVax
ompany in Cambridge, Mass. Unwittingly, in 1999, OraVax, and, its parent
company, Peptide Therapeutic of Cambridge, UK, had an article on the corporate
website regarding a chimeravax vaccine for Japanese Encephalitis family
of flaviviruses. OraVax was to field test this vaccine in Fall 1999, which
coincided with the outbreak of West Nile Fever in New York.
- Plans for this vaccine were in the works prior to 1996.
It was in 1996 when OraVax Co. was granted permission to license genetically
altered Japanese Encephalitis which had been exclusively created and patented
by the US government, Ft. Detrick.
- It is no surprise that OraVax would get the Ft. Detrick
altered encephalitis, and the subsequent grant to manufacture and market
- I had further discussed an alliance between Dr. Jerry
Hauer, former head of the Office of Emergency Management for New York City,
and Col. Dr. Thomas Monath of OraVax. Both were from our biowar research
facility at Ft. Detrick. Dr. Monath has been working closely with New York
City OEM and the CDC from August when the outbreak was allegedly said to
- OraVax had said on its own website that Phase 2 trials
were scheduled to commence this Fall 2000. We now have breaking news that
OraVax was granted 3 million dollars to develop a West Nile vaccine.
- There have been those, like myself, who knew the vaccine
was in the making and who suspected that the West Nile virus was released
on the public to create a market for the vaccine. News of this grant further
strengthens our suspicions that the outbreak was indeed ochestrated for
1. profit and 2. as a bioterrorism preparedness simulation and experiment.
- I believe that is why the virus was "allegedly"
released in New York. There have been many involved in bioterrorism preparedness
who believe New York will be hit with a bioweapon and who, like Dr. Jerry
Hauer, were vocal about the need for a real life simulation in the New
- I sincerely hope that our elected officials will make
a sincere investigation into the origin of the non-endemic West Nile outbreak.
If it is found that the virus was released on the public, I hope that those
responsible will be held accountable. There were 7 deaths last year from
the virus and it is estimated that there will be even more deaths this
year. In my book that makes anyone releasing this virus a serial killer.
- Thank you,
- West Nile Virus Vaccine Announced
By Company Linked To Giuliani
- The Financial Times - London 8-1-00
- Peptide Therapeutics, the UK biotech company, said it
had been awarded a $3m grant to develop a new vaccine to combat the mosquito-borne
West Nile virus, which killed seven The vaccine will be developed at OraVax,
Peptide's US subsidiary, using the company's proprietary ChimeriVax technology."
[see below for their detailed press release]
- For the past 10 months I have been writing about a bio-chemical
corporation, Oravax, in relation to the so-called WNV (West Nile Virus)
epidemic in NYC. The V.P of Oravax, Dr. Thomas Monath has been working
behind the scenes with Mayor Giuliani, former OEM chief Jerry Hauer, Dr.
Cohen and the CDC since the very beginning of this issue.
- From: Newsday 9/25/99-Deadly Discovery "Virologist
Thomas Monath, one of the country's leading authorities on mosquito-carried
viruses, called the discovery ``a bombshell,'' and added: `` This is the
biggest arbovirus story of the last 50 years. Wow!'' Monath, who works
for OraVax, a biotechnology company in Boston, said he has been working
closely with CDC investigators in New York since the encephalitis outbreak
began in late August. He is assisting federal scientists in trying to figure
out a way to deal with the new development."<
- As predicted, Oravax has now been given a grant from
the N.I.H. (National Institute of Health) to create a WNV vaccine. The
theory I and a number of other activists have been suggesting is that the
entire WNV panic has been created specifically in order to justify the
mass distribution of this very vaccine throughout the entire U.S.
- Oravax was granted a license by the U.S. Army bio-warfare
lab in Ft. Dietrick in 1996 (Monath was previously a researcher at the
same lab) to manufacture a Japanese encephalitis vaccine derived from a
genetically-altered virus the Army itself created. WNV is a variation of
Japanese encephalitis. Numerous medical and scientific institutions, many
run by the Federal government, have been quietly experimenting with WNV
in NYC and the surrounding area for decades [see references below]. Most
of this research involved bio-warfare applications.
- According to the press release and articles below the
vaccine is a live, attenuated vaccine (it contains live WN virus) and involves
"the construction of a chimeric virus in which the envelope genes
of yellow fever vaccine are replaced with the corresponding genes of the
target West Nile virus". In other words, the plan appears to be to
expose the entire nation orally to a genetically-modified form of WNV.
- Since the vaccine is made from a genetically-altered
strain there is no way to know exactly what other theoretically beneficial
or harmful genes may have been added. Scientists in the field of GE foods
(genetically-altered foods) have already found evidence that genes in the
pollen of these foods can become incorporated into the DNA of insects that
pollinate the GE plants. In other words it is possible to incorporate these
genes into your own DNA simply by eating the food, or in this instance,
orally taking a vaccine. _____
- From: firstname.lastname@example.org "Tappeser"
<email@example.com Organization: Oeko-Institute e.V.
- Subject: new stories from Germany
- "The German Television ZDF reported on Sunday May
21 that a German researcher found a gene transfer from genetically engineered
rapeseed to bacteria and fungi in the gut of honey bees. Prof. Hans-Hinrich
Kaatz from the Institut fºr Bienenkunde (Institute for bee research)
at the University of Jena experimented during the last three years with
honey bees on an experimental field with transgenic rapeseed in Saxony,
- Mayor Giuliani and his advisors have been massively spraying
NYC with a variety of toxic pesticides since last Fall, despite knowing
that experts in the field of mosquito control have determined that such
spraying actually increases the number of mosquitoes, makes succeeding
generations pesticide resistant and increases the incidence of mosquitoes
infected with transmissible viruses like WNV by as much as 15 times. [see:
Are Mosquito Spray Pesticides Worsening the Encephalitis Problem? http://www.chem-tox.com/brevard/index.htm
SOURCE: Journal of the American Mosquito Control Assoc, Dec;13(4):315-25,
1997 Howard JJ, Oliver New York State Department of Health, SUNY-College
ESF, Syracuse 13210, USA. Also see my articles on this http://baltech.org/lederman/spray/]
- Considering the mild nature of WNV their actions appear
to be intended to increase WNV rather than to decrease it. Dr. Cohen implied
as much two days ago. _____
- Spray It Ain't So! Round 2 On S.I.
- New York Post 8-1-00
- "Cohen said...Part of the reason for the new skeeter
woes is that between 10 and 20 percent of the bugs won't be killed by the
pesticide [the ones that are resistant to the chemicals] - and those that
live will reproduce, Cohen said....Cohen said the traps were nearly empty
in the first two days after the initial Staten Island spraying last month,
but now they're filling up again."This is not unexpected," he
- That Dr. Cohen acknowledges he knows that the spraying
would lead to new generations of pesticide resistant mosquitoes supports
the idea that the spraying is actually intended to help create a demand
for the vaccine, which the NYC officials unquestionably knew was already
in development and testing. What the real purpose of the vaccine is one
can only guess at this point. _____
- Germ Defense Plan In Peril As Its Flaws Are Revealed
- New York Times 8-7-98
- If you carefully read the very long article this is excerpted
from you will see detailed evidence of how Dr. Monath, former Giuliani
OEM chief Jerry Hauer, the president of Rockefeller University (where they
have experimented with WNV for decades) and Dr. J. Craig Venter, president
of The Institute for Genomic Research (the co-researchers and co-owners
of the Human Genome Project) have been pressuring President Clinton to
spend billions on a nationwide vaccine program against germ warfare.
- "In April, the president...and his top officials
met at the White House on April 10 with seven private scientists in the
Truman Room, where Cabinet meetings are held. For an hour, participants
say, the scientists discussed the germ topic and pushed for a vaccine stockpile.
Clinton's attending officials included the secretary of defense, the attorney
general, the secretary of health and human services, the director of Central
Intelligence and the president's national security adviser. The scientists
present were Dr. Frank Young, a former head of the Food and Drug Administration,
who moderated the panel; Dr. Joshua Lederberg, president emeritus of Rockefeller
University; Dr. Lucille Shapiro, a biologist at Stanford University; Jerome
Hauer, head of emergency management for New York City; and Dr. Barbara
Rosenberg, a biological arms-control expert at the Federation of American
Scientists, a private group. The scientific panel also had two industry
experts, both with financial ties to vaccine work. ..Dr. Thomas Monath
was identified in a White House announcement as a vice president of OraVax
and a former official of the Centers for Disease Control and the U.S. Army
Medical Research Institute of Infectious Diseases, the government's top
body for defensive germ-warfare studies...Based in Cambridge, Mass., OraVax
was founded in 1990 to tap an emerging multi-billion-dollar market in oral
vaccines and antibodies to combat infectious diseases. But the small company
kept having problems getting beyond research and bringing products to market.
By 1996 and 1997, its survival at stake, OraVax tried to win part of the
Pentagon's expanding germ work as a subcontractor to make smallpox and
other vaccines. By early this year, that work had failed to materialize
and the company's stock price was down 90 percent from $10 a share in the
initial public offering...."The way to handle it is to be open, so
people understand that I may have a potential bias," Monath said.
"I don't make it a business of taking advantage of situations in which
I'm asked to participate to push the OraVax agenda." _____
- From: http://info.med.yale.edu/EIINet/MonathSeminar.html
- (Note how the VP of Oravax, manufacturer of the encephalitis
vaccine who is advising Giuliani on this crisis, was both a researcher
at Ft. Dietrick Bio-Warfare lab and a CDC scientist.)
- "Thomas Monath is one of the world's leading arbovirologists.
He is currently Vice- President of Research and Medical Affairs at OraVax,
Inc. in Cambridge, Massachusetts. In this position he is responsible for
the scientific direction of programs on vaccine development...Prior to
this he was the Chief of the Virology Division, U.S. Army Medical Research
Institute of Infectious Diseases at Fort Detrick in Maryland. In this position
he was responsible for the development of genetically engineered vaccines
against arthropod- borne and hemorrhagic fever viruses. Between 1974 and
1988 he was the Medical Director of the Division of Vector- Borne Infectious
Diseases at the Centers for Disease Control in Fort Collins, Colorado."
- From Patricia Doyle
- Here is the way the article appears on the Peptide Theraputic
- Peptide awarded grant by NIH to develop West Nile vaccine
- Cambridge, UK - 1 August 2000 - Peptide Therapeutics
Group ("Peptide") announces that it s US subsidiary, OraVax Inc.
has been awarded a Fast-Track Small Business Innovative Research (SBIR)
grant by the US National Institutes of Health ("NIH") to develop
an important new vaccine to prevent West Nile virus disease ("West
- West Nile is a mosquito-borne viral disease that can
be fatal. The disease first occurred in the US in the summer of 1999, when
an outbreak occurred in New York in which 62 people were hospitalised with
encephalitis and seven people died. Based on antibody surveys, approximately
2.5% of New York metropolitan residents were infected, making it likely
that many had developed milder illnesses. Countless wild birds and a number
of horses also succumbed to the disease. Other US states affected were
New Jersey, Connecticut and Maryland. Several preventative measures were
taken last year, including the spraying of New York City with pesticide
in an attempt to kill the infected mosquitoes.
- Fears are growing that another outbreak could occur this
year. Infected birds and mosquitoes have been detected over a wide area
from New Jersey to Massachusetts. Public health warnings have been issued
to residents of the affected States, and intensive mosquito control is
underway in many areas. There is no vaccine, cure or specific therapy against
West Nile virus disease. The US government is actively pursuing a campaign
to combat the disease, including funding the development of vaccines for
- The grant has been awarded through Peptide's US subsidiary,
OraVax Inc. Funding under the NIH SBIR grant is provided in two consecutive
Phases, and the Fast-track mechanism ensures no delay between Phases. The
Phase 1 award, covering the first 8 months of work is for $263K. Following
successful completion of Phase1, Phase 2 of the grant will be funded at
a level of $2.7M for up to two years. The Fast-Track grant is expected
to cover the costs of research and development, including initial human
- The West Nile vaccine will be developed using Peptideís
proprietary ChimeriVax™ technology. It will be a live, attenuated
vaccine and involves the construction of a chimeric virus in which the
envelope genes of yellow fever vaccine are replaced with the corresponding
genes of the target West Nile virus. This approach has already been employed
by Peptide to develop vaccines against dengue fever (in pre-clinical development)
and Japanese encephalitis (due to commence Phase I trials shortly).
- Dr Thomas Monath, Vice President Research & Medical
Affairs of Peptide, said: "The advantages of ChimeriVax™
vaccines include their high safety profile, ability to induce protection
within a few days after a single dose, and long-lasting immunity without
the need for booster doses. A ChimeriVax™ West Nile vaccine is
therefore ideally suited for use in an impending epidemic, where rapid
immunization is required."
- Dr John Brown, Chief Executive of Peptide, said: "We
are delighted to have been selected by the US government to receive funding
to continue to develop our West Nile vaccine. The West Nile virus is one
of the most frightening to have emerged in recent years and there is no
vaccine available to protect against the disease. We are confident that
ChimeriVax™ can provide the technology to develop a vaccine that
will provide a rapid and effective solution." _____
- Enquiries: Peptide Therapeutics Group plc
- Dr John Brown, Chief Executive Tel: + 44 1223 275300
- Dr Thomas Monath, Vice President Research & Medical
Affairs Tel: +1 617 494 1339
- Web site: www.peptide.co.uk Financial Dynamics David
Yates/Sophie Pender-Cudlip Tel: +44 207 831 3113
- Notes to Editors
- 1. Peptide
- Peptide is a biopharmaceutical company developing vaccines
to prevent and treat infectious diseases. It is based in Cambridge, UK
and, through its subsidiary OraVax Inc., has operations in Cambridge, Massachusetts.
It has a broad portfolio of vaccine product candidates undergoing clinical
trials and several technology platforms that provide the basis for further
vaccine product candidates. For further information visit our web site
- 2. ChimeriVax™
- The ChimeriVax™ technology platform is a method
for development of new vaccines against viruses in the family Flaviviridae.
The technology utilizes a molecular clone of yellow fever 17D, one of the
safest and most effective vaccines ever developed, as the foundation for
construction of new live, attenuated vaccines against related Flaviviruses.
To generate a new vaccine, the genes for the viral envelope of yellow fever
17D virus are replaced with the corresponding genes of the target virus,
for example West Nile, creating a yellow fever-West Nile hybrid or ëchimeraí.
The new virus contains West Nile envelope proteins required for stimulating
immunity but retains the replicative machinery of yellow fever 17D vaccine
- The ChimeriVax™ technology is being developed
in several product programmes including vaccines against dengue fever,
Japanese encephalitis, tick-borne encephalitis and hepatitis C. Peptideís
most advanced programme using this technology is to develop a vaccine against
Japanese encephalitis, the leading cause of viral infection of the central
nervous system in Asia. Phase I trials are scheduled to commence shortly.
- 3. West Nile
- West Nile encephalitis is a mosquito-borne disease that
can cause inflammation of the spinal cord and brain and can be fatal. The
virus that causes West Nile encephalitis occurs in Europe, Africa and Asia
and was first identified in the United States in the summer of 1999. The
virus grows in birds and is transmitted by mosquitoes from birds to humans
and other mammals such as horses and cows.
- There is no vaccine, cure or specific therapy for West
Nile encephalitis. Whilst some of the symptoms of the disease can be treated,
approximately 7% of people who are hospitalised from the infection die
from it. _____
- Area Labs Have Long Studied Virus Yale, Rockefeller Began
Tests In '50s
- Newday 9-29-99
- " Epidemiologists suspect that the West Nile virus
has for the first time been isolated in humans or animals in the Western
Hemisphere, but the virus has for decades made its home in several U.S.
research laboratories, including Rockefeller University in Manhattan and
Yale University in New Haven, Conn. In fact, investigators there were the
first to grow and study the West Nile virus in the United States. The work
began in the 1950s when unidentified viral samples from around the world
arrived at Rockefeller on a steady basis."
- Mosquito From Asia Could Carry West Nile
- Newsday 5-9-00
- (AP) - In Army tests at Fort Detrick in Frederick, Md.,
japonicus was found to be the "most competent vector" [transmittter]
for West Nile virus in a laboratory setting, when compared with other mosquitoes."
- From: http://www.bioinfo.com/jev.html [from Federal Register:
March 22, 1996 (Volume 61, Number 57, Page 11812] DEPARTMENT OF DEFENSE
Notice of Intent To Grant an Exclusive License of a U.S. Government-Owned
Patent Agency: U.S. Army Medical Research and Materiel Command, DOD [Department
of Defense]. Action: Notice.
- In accordance with 37 CFR 404.7 (a)(I)(i), announcement
is made of the intent to grant an exclusive, royalty-bearing, revocable
license of U.S. Patent Application Serial Number 08/348,882, filed November
28, 1994 and entitled ``Infectious DNA Clones of Japanese Encephalitis
Virus and Attenuated Strains Japanese Encephalitis Virus Made from the
Clones'', to OraVax, Inc., 230 Albany Street, Cambridge, Massachusetts
02139. [Requests to the Army for further information should be directed
to the public affairs officer, Mr. Chuck Dasey (301) 619-2736]
- Robert Lederman, President of A.R.T.I.S.T. (Artists,Äô
Response To Illegal State Tactics) ARTISTpres@aol.com (718) 743-3722 http://www.levymultimedia.com/lederman/index.htm
For an article on the Manhattan Institute go to http://www.konformist.com/2000/rudyg.htm
- If you would like to help oppose the spraying, please
write to the No Spray Coalition, PO Box 334, Peck Slip Station, NYC 10272-0334,
or call the No Spray hotline at (718) 670-7110. Any funds you can send
to help continue the lawsuit and this work are greatly appreciated. http://www.nospray.org/
- For Lederman articles with more on this information see
- Bugged by Spraying
- Newsday 10-10-99
- The loudest protests heard during the city's recent campaign
of insecticide spraying came from the city's tiny Green Party and the artist-agitator
Robert Lederman...Yesterday, the head of the mayor's Office of Emergency
Management, which took the lead in the assault on the city's mosquito populace,
dismissed such concerns as "irresponsible environmental hysteria and
stupidity." "If they took a deep breath [of Malathion?] and looked
at what we did and what pains we went through to ensure that we did it
right and recognize that human life is at stake, they'd get the perspective,"
said OEM Director Jerry Hauer.,Äù _____
- From: ARTISTpres@aol.com
- Date: Wed 8-2-00
- Subject: Fwd: Award granted for W. Nile vaccine
- BETHESDA, Md. - The National Institutes of Health has
awarded a Massachusetts biotechnology firm $3 million to try to create
a vaccine for the potentially fatal West Nile virus. Tuesday,Äôs
announcement comes as several Northeastern states are trying to educate
the public about the disease and kill mosquitoes that carry it.
- The virus killed seven people and sickened more than
60 in the New York City area last year, its first appearance in the Western
- The company, OraVax Inc., plans to develop the West Nile
vaccine using a proven 60-year-old yellow fever vaccine.
- "This is a live viral vaccine like one for measles
or mumps or polio," said Thomas Monath, OraVax,Äôs vice
president of research and medical affairs. ,ÄúIt will cause
a very mild infection with no symptoms and leave the person immunized against
West Nile.,Äù Monath said human testing could begin within
- OraVax, a Cambridge, Mass.-based subsidiary of Britain,Äôs
Peptide The virus killed seven people and sickened more than 60 in the
New York City area last year, its first appearance in the Western Hemisphere.
Therapeutics Group, has been working on a West Nile vaccine since last
- No human deaths have been reported this year, but mosquitoes
carrying the virus have been found in parts of New York, and the virus
has shown up in birds there and elsewhere in the Northeast.
Site Served by TheHostPros